CINECA IRIS Institutional Research Information System

BOCCACCINO, ALESSANDRA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.705
AS - Asia 1.121
EU - Europa 733
SA - Sud America 147
Continente sconosciuto - Info sul continente non disponibili 71
AF - Africa 58
OC - Oceania 2
Totale 3.837
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.662
SG - Singapore 422
IT - Italia 314
CN - Cina 274
HK - Hong Kong 163
BR - Brasile 120
VN - Vietnam 94
SE - Svezia 87
DE - Germania 77
GB - Regno Unito 58
FR - Francia 47
IN - India 35
FI - Finlandia 33
BG - Bulgaria 28
JP - Giappone 24
CI - Costa d'Avorio 23
CA - Canada 22
NL - Olanda 17
BD - Bangladesh 16
PL - Polonia 15
ID - Indonesia 14
KR - Corea 14
AR - Argentina 12
MX - Messico 11
RU - Federazione Russa 11
TR - Turchia 10
UA - Ucraina 10
NG - Nigeria 9
ES - Italia 8
LT - Lituania 7
PK - Pakistan 7
SN - Senegal 6
IQ - Iraq 5
PH - Filippine 5
UZ - Uzbekistan 5
CR - Costa Rica 4
CZ - Repubblica Ceca 4
MY - Malesia 4
ZA - Sudafrica 4
AT - Austria 3
CL - Cile 3
CO - Colombia 3
EC - Ecuador 3
IE - Irlanda 3
KG - Kirghizistan 3
TH - Thailandia 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AM - Armenia 2
AO - Angola 2
AZ - Azerbaigian 2
DO - Repubblica Dominicana 2
EG - Egitto 2
ET - Etiopia 2
GT - Guatemala 2
IR - Iran 2
JO - Giordania 2
KH - Cambogia 2
MA - Marocco 2
NZ - Nuova Zelanda 2
PE - Perù 2
PS - Palestinian Territory 2
PT - Portogallo 2
SY - Repubblica araba siriana 2
TN - Tunisia 2
UY - Uruguay 2
VE - Venezuela 2
BF - Burkina Faso 1
BS - Bahamas 1
CG - Congo 1
DK - Danimarca 1
GE - Georgia 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
JM - Giamaica 1
KE - Kenya 1
KW - Kuwait 1
KZ - Kazakistan 1
LB - Libano 1
LY - Libia 1
MT - Malta 1
NA - Namibia 1
NP - Nepal 1
RO - Romania 1
RS - Serbia 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TG - Togo 1
Totale 3.766
Salva come PNG Salva come JPEG
Città #
Singapore 247
Ashburn 216
Dallas 193
Hong Kong 155
Santa Clara 134
San Jose 117
Chandler 81
Fairfield 70
Shanghai 58
Florence 47
New York 47
Los Angeles 45
Wilmington 40
London 39
Munich 39
Council Bluffs 37
Beijing 36
Boardman 35
Seattle 35
Pisa 32
Ho Chi Minh City 28
Sofia 28
Cambridge 27
Abidjan 23
Woodbridge 22
Hefei 21
Hanoi 20
Tokyo 20
Milan 19
Cascina 18
Turku 18
Princeton 17
Frankfurt am Main 16
Lawrence 16
Helsinki 15
São Paulo 15
Lauterbourg 14
Ogden 14
Seoul 14
Warsaw 14
Bremen 13
Colorado Springs 13
Genoa 13
Houston 13
Medford 12
Turin 12
Orem 11
Redondo Beach 11
Buffalo 10
Rome 10
Serra 10
Lagos 9
Ann Arbor 8
Montreal 7
Toronto 7
Curitiba 6
Dakar 6
Denver 6
Istanbul 6
Phoenix 6
Quanzhou 6
San Diego 6
Verona 6
Baltimore 5
Da Nang 5
Kent 5
Seacroft 5
Tashkent 5
Washington 5
Baghdad 4
Brooklyn 4
Dhaka 4
Fortaleza 4
Fuzhou 4
Karachi 4
Mumbai 4
Ottawa 4
Polverigi 4
Porto Alegre 4
Redwood City 4
Atlanta 3
Bari 3
Bishkek 3
Chennai 3
Coreglia Antelminelli 3
Dublin 3
Düsseldorf 3
Gargallo 3
Jakarta 3
Mexico City 3
Olomouc 3
Pistoia 3
Portsmouth 3
Qingdao 3
Querétaro 3
San José 3
Stockholm 3
Tangerang 3
Thái Nguyên 3
Vienna 3
Totale 2.423
Salva come PNG Salva come JPEG
Nome #
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 196
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis 195
Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials 185
Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable 174
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases 169
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study 169
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component 168
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 160
AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer 155
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 152
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 138
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 137
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies 137
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies 133
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients 130
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study 130
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies 123
Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy—a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest 115
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: A pooled analysis of TRIBE and TRIBE2 studies 108
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer 104
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial 103
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature 103
Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials 102
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience 100
Treatment of patients with BRAFV600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset 81
Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study 70
null 65
Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO 58
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population 47
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 41
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab 39
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 35
null 15
Totale 3.837
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.321
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.321
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022131 0 0 2 0 21 24 2 5 5 16 16 40
2022/2023340 25 51 20 24 33 33 17 20 56 2 50 9
2023/2024302 11 24 39 33 34 42 22 14 5 14 39 25
2024/20251.085 36 41 28 62 87 137 75 49 119 97 125 229
2025/20261.485 124 160 169 110 159 119 233 100 105 152 32 22
2026/2027210 41 169 0 0 0 0 0 0 0 0 0 0
Totale 3.837